VHL Polyclonal Antibody

Sizes: 50μL, 100μL

Catalogue Numbers: RA36058-50, RA36058-100

Citations, Manuals and MSDS Available upon request.

Background: von Hippel-Lindau tumor suppressor (VHL) Homo sapiens Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008],

Condition: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage Instructions: -20°C/1 year

Recommended dilutions: IHC-p 1:50-200, ELISA 1:10000-20000

Alternative Names: Von Hippel-Lindau disease tumor suppressor (Protein G7;pVHL)

Applications: IHC-p; IF (paraffin section) ; ELISA

Species Cross-Reactivity: Human; Rat; Mouse

GeneID (Human): 7428

SWISS: P40337

Source: Rabbit

Research Use Only